Conflict of interest None declared.
Peroxisome proliferator-activated receptor gamma, a possible culprit in mycosis fungoides: an immunohistochemical study
Article first published online: 24 NOV 2011
© 2011 The Authors. Journal of the European Academy of Dermatology and Venereology © 2011 European Academy of Dermatology and Venereology
Journal of the European Academy of Dermatology and Venereology
Volume 26, Issue 12, pages 1522–1532, December 2012
How to Cite
Youssef, R., Hegazy, R.A., Fawzy, M.M., Abdel Halim, D.M., Nabil, N., Sayed, S.S. and Shaker, O.G. (2012), Peroxisome proliferator-activated receptor gamma, a possible culprit in mycosis fungoides: an immunohistochemical study. Journal of the European Academy of Dermatology and Venereology, 26: 1522–1532. doi: 10.1111/j.1468-3083.2011.04333.x
Funding sources None.
- Issue published online: 14 NOV 2012
- Article first published online: 24 NOV 2011
- Received: 6 May 2011; Accepted: 18 October 2011
Background It still remains debatable whether peroxisome proliferator-activated receptor gamma (PPARγ) is pro- or antineoplastic, and its exact role in mycosis fungoides (MF) remains unclear.
Objective This prospective comparative study aimed to investigate the expression of PPARγ in MF and compare it with psoriatics and controls in a trial to deduce its possible role in MF. Also, we tried to clarify the relation between PPARγ and Bcl-2 in MF.
Methods Twenty MF patients, 20 psoriatic patients and 20 controls were included. All participants underwent a skin biopsy, and immunohistochemical staining for both PPARγ and Bcl-2 were performed. Western blot analysis was performed for detection of both PPARγ and Bcl-2.
Results The mean area per cent of PPARγ measured in the MF patients (57.1217 ± 9.502417) was significantly higher (P < 0.001) when compared with that of both the psoriatics (2.989 ± 1.723) and controls (35.9357 ± 8.1789). The mean area per cent of Bcl-2 in MF patients (9.3763 ± 6.6328) was significantly higher (P < 0.001) than that of both the psoriatics (2.35 ± 1.35) and the controls (0.73105 ± 0.5302)]. Our results were confirmed using the western blot analysis. We detected a highly significant positive correlation between the PPARγ and Bcl-2 mean area per cents in all patients. In our MF patients, both parameters were also positively correlated with the age of the patient, duration and stage of MF (P < 0.05).
Conclusion Our data suggest a possible role for PPARγ in the pathogenesis of MF possibly through several mechanisms, one of which might be conferring upon the lymphoma cells, a survival advantage at least partially through up regulating Bcl-2.